Leflaw.com

Skip to content

You are here: Home

Raxar

Raxar, an antibiotic manufactured by Glaxo Wellcome and approved by the FDA in 1997, was used to treat bacterial infections such as bronchitis, community-acquired pneumonia, gonorrhea, urethritis, and cervicitis.

In 1999 Raxar was removed from the market after questions regarding its safety were raised. Raxar was shown to prolong the heart's QT interval. This prolongation may result in a ventricular arrhythmia known as torsades de pointes. Although rare, such a reaction to Raxar can be fatal. Since Raxar's approval, over 2.65 million prescriptions have been written.

Raxar oral fluoroquinolone antibiotic was prescribed to an estimated 2.65 million patients from when Raxar was first marketed in August 1997 until the October 1997 recall. Raxar was intended to treat a variety of infections, such as pneumonia, bronchitis, and some sexually transmitted infections. The antibiotic has been linked to serious side effects including Raxar prolonging the heart's QT interval that can lead to ventricular arrhythmia that can become fatal.

Raxar manufacturer, GlaxoWellcome has been in violation of FDA regulations for misleading information as well. The FDA required any Raxar promotional materials to be discontinued that were in violation in addition to writing a letter containing the company's intent to comply with the FDA's requests regarding Raxar. If you would like more information regarding Raxar please contact us.

Fill Out a Form

Defective Drugs Form

Basic Information

Name

Email

Phone

State of Residence

DOB

Details About Injury

Drug Complained of:

When Did You Take This Drug?

Describe Your Injury

Are you human?

FDA Recalls

Food and Drug Administration--Recalls/Safety Alerts

Bakery El Monte Sinai Corp Announces Allergy Alert on Undeclared Eggs in Rainbow Cake
Bakery El Monte Sinai Corp., located at 100 A North Franklin Street in Hempstead, New York 11550, is recalling rainbow cake because it may contain undeclared eggs.
Hospira Announces A Nationwide Voluntary Recall Of One Lot Of Hydromorphone Hydrochloride Injection 1 MG/ML, (C-II) 1 ML Fill In 2.5 ML Carpuject, That May Contain More Than The Intended Fill Volume
Hospira, Inc. (NYSE: HSP), announced today it is initiating a voluntary user level recall of one lot of Hydromorphone Injection, USP, 1 mg/mL (C-II), 1 mL fill in 2.5 mL Carpuject, NDC 0409-1283-31, due to two reported complaints of a single Carpuject containing more than the 1 mL labeled fill volume. Opioid pain medications such as Hydromorphone have life-threatening consequences if overdosed.
NestlÃ© Purina Voluntarily Recalls Single Lot of Therapeutic Canned Cat Food Due to A Low Level of Thiamine (Vitamin B1)
NestlÃ© Purina PetCare (NPP) is voluntarily recalling one specific lot of its Purina Veterinary DietsÂ® OM Overweight Management canned cat food, available through veterinarians in the U.S. and Canada. This precautionary measure is being taken in response to one consumer complaint received by FDA.